153 related articles for article (PubMed ID: 34699294)
21. SARS-CoV-2 antibodies in Ontario health care workers during and after the first wave of the pandemic: a cohort study.
Science M; Bolotin S; Silverman M; Nadarajah J; Maguire B; Parekh RS; McGeer A; Schwartz KL; Alexander L; Allen U; Ariyarajah A; Castellani L; Cohn RD; Downing M; Katz K; Kazmi K; Leis JA; Liu D; Pernica JM; Schneiderman JE; Sumaida M; Campigotto A
CMAJ Open; 2021; 9(4):E929-E939. PubMed ID: 34642255
[TBL] [Abstract][Full Text] [Related]
22. SARS-CoV-2 seroprevalence in the city of Puerto Madryn: Underdiagnosis and relevance of children in the pandemic.
Schonfeld D; Fernández H; Ramírez J; Acosta D; Becerra J; Wettstein M; Strella T; Vaccaro M; Arias S; Rodríguez Calvo V; Neme R; Pérez-Chada D
PLoS One; 2022; 17(3):e0263679. PubMed ID: 35286328
[TBL] [Abstract][Full Text] [Related]
23. Persistence of SARS-CoV-2-Specific Antibodies for 13 Months after Infection.
Kučinskaitė-Kodzė I; Simanavičius M; Šimaitis A; Žvirblienė A
Viruses; 2021 Nov; 13(11):. PubMed ID: 34835119
[TBL] [Abstract][Full Text] [Related]
24. Prevalence of COVID-19 Virus Infection in Semnan province.
Jandaghi E; Hemati M; Mohammadlou M; Jandaghi J; Mirmohammadkhani M; Danaei N; Kokhaei P
Iran J Immunol; 2021 Mar; 18(1):74-81. PubMed ID: 33787516
[TBL] [Abstract][Full Text] [Related]
25. Prevalence of IgG antibodies against SARS-CoV-2 among healthcare workers in a tertiary pediatric hospital in Poland.
Kasztelewicz B; Janiszewska K; Burzyńska J; Szydłowska E; Migdał M; Dzierżanowska-Fangrat K
PLoS One; 2021; 16(4):e0249550. PubMed ID: 33793673
[TBL] [Abstract][Full Text] [Related]
26. SARS-CoV-2 Seroprevalence Structure of the Russian Population during the COVID-19 Pandemic.
Popova AY; Smirnov VS; Andreeva EE; Babura EA; Balakhonov SV; Bashketova NS; Bugorkova SA; Bulanov MV; Valeullina NN; Vetrov VV; Goryaev DV; Detkovskaya TN; Ezhlova EB; Zaitseva NN; Istorik OA; Kovalchuk IV; Kozlovskikh DN; Kombarova SY; Kurganova OP; Lomovtsev AE; Lukicheva LA; Lyalina LV; Melnikova AA; Mikailova OM; Noskov AK; Noskova LN; Oglezneva EE; Osmolovskaya TP; Patyashina MA; Penkovskaya NA; Samoilova LV; Stepanova TF; Trotsenko OE; Totolian AA
Viruses; 2021 Aug; 13(8):. PubMed ID: 34452512
[TBL] [Abstract][Full Text] [Related]
27. SARS-CoV-2 antibody seroprevalence in India, August-September, 2020: findings from the second nationwide household serosurvey.
Murhekar MV; Bhatnagar T; Selvaraju S; Saravanakumar V; Thangaraj JWV; Shah N; Kumar MS; Rade K; Sabarinathan R; Asthana S; Balachandar R; Bangar SD; Bansal AK; Bhat J; Chopra V; Das D; Deb AK; Devi KR; Dwivedi GR; Khan SMS; Kumar CPG; Kumar MS; Laxmaiah A; Madhukar M; Mahapatra A; Mohanty SS; Rangaraju C; Turuk A; Baradwaj DK; Chahal AS; Debnath F; Haq I; Kalliath A; Kanungo S; Kshatri JS; Lakshmi GGJN; Mitra A; Nirmala AR; Prasad GV; Qurieshi MA; Sahay S; Sangwan RK; Sekar K; Shukla VK; Singh PK; Singh P; Singh R; Varma DS; Viramgami A; Panda S; Reddy DCS; Bhargava B;
Lancet Glob Health; 2021 Mar; 9(3):e257-e266. PubMed ID: 33515512
[TBL] [Abstract][Full Text] [Related]
28. Prevalence of SARS-CoV-2 antibodies in hemodialysis patients in Senegal: a multicenter cross-sectional study.
Seck SM; Mbow M; Kane Y; Cisse MM; Faye G; Kama A; Sarr M; Nitcheu P; Dahaba M; Diallo IM; Diawara MS; Latou LNM; Dia Y; Mboup S
BMC Nephrol; 2021 Nov; 22(1):384. PubMed ID: 34789170
[TBL] [Abstract][Full Text] [Related]
29. Seroprevalence of SARS-CoV-2 Infection in Portugal in May-July 2020: Results of the First National Serological Survey (ISNCOVID-19).
Kislaya I; Gonçalves P; Barreto M; Sousa R; Garcia AC; Matos R; Guiomar R; Rodrigues AP;
Acta Med Port; 2021 Feb; 34(2):87-94. PubMed ID: 33641702
[TBL] [Abstract][Full Text] [Related]
30. Seroprevalence of SARS-CoV-2 Antibodies in Children and Adults in St. Louis, Missouri, USA.
Smith BK; Janowski AB; Danis JE; Harvey IB; Zhao H; Dai YN; Farnsworth CW; Gronowski AM; Roper S; Fremont DH; Wang D
mSphere; 2021 Feb; 6(1):. PubMed ID: 33536325
[TBL] [Abstract][Full Text] [Related]
31. Seroprevalence of antibodies to SARS-CoV-2 among blood donors in the early months of the pandemic in Saudi Arabia.
Banjar A; Al-Tawfiq JA; Alruwaily A; Alserehi H; Al-Qunaibet A; Alaswad R; Almutlaq H; Almudaiheem A; Khojah AT; Alsaif F; Almolad SK; Alqahtani S; AlJurayyan A; Alotaibi A; Almalki S; Abuhaimed Y; Alkhashan A; Alfaifi A; Alabdulkareem K; Jokhdar H; Assiri A; Almudarra S
Int J Infect Dis; 2021 Mar; 104():452-457. PubMed ID: 33465488
[TBL] [Abstract][Full Text] [Related]
32. Kinetics of SARS-CoV-2 Specific and Neutralizing Antibodies over Seven Months after Symptom Onset in COVID-19 Patients.
Zhu L; Xu X; Zhu B; Guo X; Xu K; Song C; Fu J; Yu H; Kong X; Peng J; Huang H; Zou X; Ding Y; Bao C; Zhu F; Hu Z; Wu M; Shen H
Microbiol Spectr; 2021 Oct; 9(2):e0059021. PubMed ID: 34550000
[TBL] [Abstract][Full Text] [Related]
33. SARS-CoV-2 seroprevalence among blood donors after the first COVID-19 wave in Canada.
Saeed S; Drews SJ; Pambrun C; Yi QL; Osmond L; O'Brien SF
Transfusion; 2021 Mar; 61(3):862-872. PubMed ID: 33527398
[TBL] [Abstract][Full Text] [Related]
34. Prevalence of Anti-SARS-CoV-2 Specific Antibodies in Health-Care Workers Compared to General Population during an Early Phase of the Pandemic, Tehran-Iran.
Mortezagholi S; Rostamzadeh D; Alinejad M; Younesi V; Tabarsi P; Shabani M
Iran J Immunol; 2021 Mar; 18(1):82-92. PubMed ID: 33787517
[TBL] [Abstract][Full Text] [Related]
35. High SARS-CoV-2 seroprevalence in Karaganda, Kazakhstan before the launch of COVID-19 vaccination.
Kadyrova I; Yegorov S; Negmetzhanov B; Kolesnikova Y; Kolesnichenko S; Korshukov I; Akhmaltdinova L; Vazenmiller D; Stupina Y; Kabildina N; Ashimova A; Raimbekova A; Turmukhambetova A; Miller MS; Hortelano G; Babenko D
PLoS One; 2022; 17(7):e0272008. PubMed ID: 35895743
[TBL] [Abstract][Full Text] [Related]
36. Seroprevalence of SARS-CoV-2 antibody among urban Iranian population: findings from the second large population-based cross-sectional study.
Zamani M; Poustchi H; Mohammadi Z; Dalvand S; Sharafkhah M; Motevalian SA; Eslami S; Emami A; Somi MH; Yazdani-Charati J; Saki N; Karami M; Najafi F; Mohebbi I; Veisi N; Hormati A; Pourfarzi F; Ghadimi R; Ansari-Moghaddam A; Sharifi H; Roshandel G; Mansour-Ghanaei F; Joukar F; Shayanrad A; Eghtesad S; Niavarani A; Delavari A; Kaveh S; Feizesani A; Markarian M; Shafighian F; Sadjadi A; Darvishian M; Malekzadeh R
BMC Public Health; 2022 May; 22(1):1031. PubMed ID: 35606743
[TBL] [Abstract][Full Text] [Related]
37. SARS-CoV-2 Seroprevalence Trends in the Netherlands in the Variant of Concern Era: Input for Future Response.
Vos ERA; van Hagen CCE; Wong D; Smits G; Kuijer M; Wijmenga-Monsuur AJ; Kaczorowska J; van Binnendijk RS; van der Klis FRM; den Hartog G; de Melker HE
Influenza Other Respir Viruses; 2024 Jun; 18(6):e13312. PubMed ID: 38837866
[TBL] [Abstract][Full Text] [Related]
38. Insights from Patterns of SARS-CoV-2 Immunoglobulin G Serology Test Results from a National Clinical Laboratory, United States, March-July 2020.
Kaufman HW; Chen Z; Meyer WA; Wohlgemuth JG
Popul Health Manag; 2021 Feb; 24(S1):S35-S42. PubMed ID: 33216694
[TBL] [Abstract][Full Text] [Related]
39. Provider Antibody Serology Study of Virus in the Emergency Room (PASSOVER) Study: Special Population COVID-19 Seroprevalence.
Heyming TW; Sanger T; Tongol A; Schomberg J; Bacon K; Lara B
West J Emerg Med; 2021 Apr; 22(3):565-571. PubMed ID: 34125028
[TBL] [Abstract][Full Text] [Related]
40. Estimate of anti-SARS-CoV-2 spike IgG antibodies prevalence among Iranian population based on blood donations: A serial cross-sectional study during the third wave of the pandemic.
Ranjbar Kermani F; Arabkhazaeli A; Eshghi P; Maghsudlu M; Amini-Kafiabad S; Teimourpour A; Pourkarim MR
Transfus Clin Biol; 2023 Feb; 30(1):123-129. PubMed ID: 36084918
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
